Little Green Pharma (ASX:LGP) welcomed the French government's notification to the European Commission of the production and market authorization framework for medicinal cannabis, which establishes the pathway for full market legalization, according to a Wednesday Australian bourse filing.
It noted that the firm will continue to be one of the only two authorized companies supplying products at full price during the transition period to March 31, 2026, under the new framework.
All medicinal cannabis products will now require a common technical document submission for market authorization. The firm anticipates that the number of firms entering the French market will be limited, given the strict data requirements.
Its shares fell 4% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.